• 1
    Choi HK, Adimoelja A, Kim SC, Soebadi DM, Seong DH, Garceau RJ. A dose–response study of alprostadil sterile powder (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men. Int J Impotence Res 1997; 9: 4751
  • 2
    Levine SB, Althof SE, Turner LA et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 547
  • 3
    Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 15645
  • 4
    Vardi Y, Sprecher E, Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol 2000; 163: 46770
  • 5
    Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self injection therapy for impotence. Int J Import Res 1994; 6: 1714
  • 6
    Sundaram CP, Thomas W, Pryor LE et al. Long term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 9325
  • 7
    Morales A, Gingell C, Collins M et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 6973
  • 8
    Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397404
  • 9
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 30511
  • 10
    Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy. efficacy and preference in patients on intracavernous injection for more than 1 year. Urology 2000; 164: 1197200
  • 11
    Cheeitlin MD, Hutter AM, Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273 82
  • 12
    Viagra Labelling information. NDA submission, Pfizer (New York, NY), 1997